Galderma doubles up on Nemluvio approvals

Swiss dermatology company Galderma (GALD.SW) has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and—as reported previously—Swissmedic have granted marketing authorization for the subcutaneous use of the drug for moderate-to-severe atopic dermatitis alongside topical corticosteroids and/or calcineurin inhibitors in patients aged 12 years and older with a body weight of at least 30kg, who are candidates for systemic therapy, and for moderate-to-severe prurigo nodularis patients who are candidates for systemic therapy.

These are the first approvals from countries within the Access Consortium framework, an international collaborative initiative comprised of regulatory authorities which work together to address shared challenges.